MX2015009681A - Un medicamento combinado que comprende finilefrina y paracetamol. - Google Patents
Un medicamento combinado que comprende finilefrina y paracetamol.Info
- Publication number
- MX2015009681A MX2015009681A MX2015009681A MX2015009681A MX2015009681A MX 2015009681 A MX2015009681 A MX 2015009681A MX 2015009681 A MX2015009681 A MX 2015009681A MX 2015009681 A MX2015009681 A MX 2015009681A MX 2015009681 A MX2015009681 A MX 2015009681A
- Authority
- MX
- Mexico
- Prior art keywords
- phenylephrine
- paracetamol
- pharmaceutically acceptable
- alternative form
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
El uso de hidrocloruro de finilefrina (o una cantidad equivalente de una forma alternativa farmacéuticamente aceptable de fenilefrina) y paracetamol en la producción de un medicamento combinado para el tratamiento de la congestión de las mucosas de las vías respiratorias superiores, medicamento que comprende la combinación de tales sustancias con excipientes, caracterizado porque el medicamento contiene el hidrocloruro de finilefrina (o la cantidad equivalente de una forma alternativa farmacéuticamente aceptable de fenilefrina) y paracetamol en las proporciones adecuadas para, y el medicamento es para, suministrarle a un adulto: a 4 mg - 7,5 mg de hidrocloruro de fenilefrina (o una cantidad equivalente de una forma alternativa farmacéuticamente aceptable de fenilefrina), en combinación con 950 mg - 1000 mg de paracetamol; o b 5 mg - 7,5 mg de hidrocloruro de fenilefrina (o una cantidad equivalente de una forma alternativa farmacéuticamente aceptable de fenilefrina), en combinación con 600 mg - 700mg de paracetamol; c 6 mg - 8 mg de hidrocloruro de fenilefrina (o una cantidad equivalente de una forma alternativa farmacéuticamente aceptable de fenilefrina), en combinación con 500 mg - 550 mg de paracetamol.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ60665913 | 2013-02-04 | ||
| NZ61013213 | 2013-05-02 | ||
| NZ61391813 | 2013-08-02 | ||
| NZ61802713 | 2013-11-20 | ||
| PCT/NZ2014/000001 WO2014120021A1 (en) | 2013-02-04 | 2014-01-07 | A combination medicament comprising phenylephrine and paracetamol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015009681A true MX2015009681A (es) | 2016-07-11 |
Family
ID=51262632
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015009681A MX2015009681A (es) | 2013-02-04 | 2014-01-07 | Un medicamento combinado que comprende finilefrina y paracetamol. |
| MX2021001845A MX2021001845A (es) | 2013-02-04 | 2015-07-27 | Un medicamento combinado que comprende fenilefrina y paracetamol. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001845A MX2021001845A (es) | 2013-02-04 | 2015-07-27 | Un medicamento combinado que comprende fenilefrina y paracetamol. |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP2830605B8 (es) |
| CN (2) | CN107811999A (es) |
| AP (1) | AP2015008704A0 (es) |
| BR (1) | BR112015015938A2 (es) |
| CA (1) | CA2893836C (es) |
| EC (1) | ECSP15033649A (es) |
| LU (1) | LU92526B1 (es) |
| MX (2) | MX2015009681A (es) |
| PE (1) | PE20151282A1 (es) |
| PH (1) | PH12015501294A1 (es) |
| PL (1) | PL2830605T3 (es) |
| RS (1) | RS64807B1 (es) |
| SG (1) | SG11201504389QA (es) |
| TW (1) | TW201434464A (es) |
| WO (1) | WO2014120021A1 (es) |
| ZA (1) | ZA201504080B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070249727A1 (en) | 2006-04-21 | 2007-10-25 | The Proctor & Gamble Company | Compositions and kits useful for treatment of respiratory illness |
| US10022339B2 (en) | 2006-04-21 | 2018-07-17 | The Procter & Gamble Company | Compositions and methods useful for treatment of respiratory illness |
| EP3095466B1 (en) | 2015-05-21 | 2020-12-16 | Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. | Pharmaceutical formulations with improved solubility and stability |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4260600A (en) * | 1979-10-22 | 1981-04-07 | Ronald Valle | Method of treating depression |
| US20040162273A1 (en) * | 2003-01-23 | 2004-08-19 | The Procter & Gamble Company | Powder pharmaceutical compositions |
| GB2443793B (en) | 2006-04-05 | 2010-12-01 | Reckitt Benckiser Healthcare | Product, method of manufacture and use |
| US20070254027A1 (en) * | 2006-04-28 | 2007-11-01 | The Procter & Gamble Company | Compositions and methods useful for treatment of respiratory illness |
| CA2731801C (en) | 2007-07-23 | 2013-11-26 | Kingsway Pharmaceuticals Inc. | Therapeutic formulations for the treatment of cold and flu-like symptoms |
| CA2716923A1 (en) * | 2008-03-17 | 2009-09-24 | The Procter & Gamble Company | User-customizable dosing system |
| US8518439B2 (en) * | 2008-12-03 | 2013-08-27 | Novartis Ag | Liquid therapeutic composition |
| US20110104272A1 (en) * | 2009-11-05 | 2011-05-05 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine |
| WO2012090218A1 (en) * | 2010-12-30 | 2012-07-05 | Zota Health Care Ltd | Synergistic effects of the combination of the specific compounds with paracetamol and their effects on various diseases |
-
2014
- 2014-01-07 CN CN201711276478.7A patent/CN107811999A/zh active Pending
- 2014-01-07 MX MX2015009681A patent/MX2015009681A/es unknown
- 2014-01-07 LU LU92526A patent/LU92526B1/xx active
- 2014-01-07 BR BR112015015938A patent/BR112015015938A2/pt not_active Application Discontinuation
- 2014-01-07 EP EP14746905.0A patent/EP2830605B8/en active Active
- 2014-01-07 SG SG11201504389QA patent/SG11201504389QA/en unknown
- 2014-01-07 PL PL14746905.0T patent/PL2830605T3/pl unknown
- 2014-01-07 CN CN201480003659.0A patent/CN104936585B/zh active Active
- 2014-01-07 PE PE2015001231A patent/PE20151282A1/es unknown
- 2014-01-07 WO PCT/NZ2014/000001 patent/WO2014120021A1/en active Application Filing
- 2014-01-07 RS RS20230953A patent/RS64807B1/sr unknown
- 2014-01-07 AP AP2015008704A patent/AP2015008704A0/xx unknown
- 2014-01-07 CA CA2893836A patent/CA2893836C/en not_active Expired - Fee Related
- 2014-01-29 TW TW103103365A patent/TW201434464A/zh not_active IP Right Cessation
-
2015
- 2015-06-05 ZA ZA2015/04080A patent/ZA201504080B/en unknown
- 2015-06-05 PH PH12015501294A patent/PH12015501294A1/en unknown
- 2015-07-27 MX MX2021001845A patent/MX2021001845A/es unknown
- 2015-08-03 EC ECIEPI201533649A patent/ECSP15033649A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014120021A1 (en) | 2014-08-07 |
| PL2830605T3 (pl) | 2024-02-19 |
| LU92526B1 (fr) | 2014-12-22 |
| EP2830605B1 (en) | 2023-09-27 |
| ECSP15033649A (es) | 2015-11-30 |
| BR112015015938A2 (pt) | 2017-07-11 |
| AP2015008704A0 (en) | 2015-09-30 |
| CA2893836C (en) | 2017-05-02 |
| CN107811999A (zh) | 2018-03-20 |
| PE20151282A1 (es) | 2015-10-04 |
| TW201434464A (zh) | 2014-09-16 |
| CN104936585A (zh) | 2015-09-23 |
| EP2830605A4 (en) | 2015-02-04 |
| RS64807B1 (sr) | 2023-12-29 |
| SG11201504389QA (en) | 2015-08-28 |
| CA2893836A1 (en) | 2014-08-07 |
| PH12015501294A1 (en) | 2015-08-24 |
| EP2830605B8 (en) | 2023-11-08 |
| CN104936585B (zh) | 2017-11-14 |
| MX2021001845A (es) | 2021-05-13 |
| ZA201504080B (en) | 2016-04-28 |
| EP2830605A1 (en) | 2015-02-04 |
| TWI514998B (es) | 2016-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015016983A (es) | Moduladores del transporte nuclear y usos de los mismos. | |
| PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MY189466A (en) | Methods of modulating drug plasma levels using erythrohydroxybupropion | |
| PH12015501600A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| IN2013MU03583A (es) | ||
| MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
| MX2021002322A (es) | Nuevos metodos. | |
| IN2013MU00711A (es) | ||
| MX2020002310A (es) | Formas de dosificacion de alta concentracion de pridopidina. | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| MX2021004883A (es) | Metodos y composiciones para tratar apnea del sue?o. | |
| MX2021001845A (es) | Un medicamento combinado que comprende fenilefrina y paracetamol. | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| NZ726131A (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| PH12016501101A1 (en) | Veliparib in combination with carboplatin for the treatment of triple negative breast cancer | |
| IN2013MU03428A (es) | ||
| PH12016502107A1 (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders | |
| IN2013MU02015A (es) | ||
| TN2014000484A1 (en) | Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis. | |
| AR095149A1 (es) | Medicamento que comprende fenilefrina y paracetamol | |
| CR20150363A (es) | Combinación de un medicamento que comprende fenilefrina y paracetamol | |
| EA201592232A1 (ru) | Применение денцихина в получении лекарственного средства для лечения тромбоцитопении | |
| AR100910A1 (es) | Forma de dosificación oral de liberación sostenida que contiene morfina y naloxona |